Most patients experience significant enlarged prostate (BPH) symptom relief after treatment with TherMatx® Office Thermo TherapyTM. Here are some findings from clinical studies:
- Proven Safety - TherMatrx received FDA approval in 2001. Since that time, more than 60,000 men have safely benefited from the therapy. In clinical trials, no long-term side effects were observed, and all treatment side effects were minor and quickly went away on their own. 1
- Significant Improvement in Symptoms - The AUA (American Urological Association) BPH Symptom Score questionnaire helps determine the severity of a patient's enlarged prostate symptoms by assigning them a number. The AUA Symptom Score was used in clinical studies to measure how much symptoms were improved after treatment with TherMatrx. 12 months after treatment with TherMatrx, AUA Symptom Scores improved by 47%. 1
- Improved Quality of Life - Perhaps the most important measure of how well a treatment works is its effect on quality of life. 12 months after treatment with TherMatrx, patients in clinical studies reported a 49% increase in their quality of life. 2
- Minimal Sexual Side Effects - In the clinical study, less than 1% of men treated with TherMatrx had a decrease in sexual function as a result of treatment. 2, 3
1. Transurethral Microwave Thermotherapy System. TherMatrx TMx-2000™. PMA P000043 summary of safety and effectiveness data. Approved June 29, 2001. Available at: www.fda.gov/cdrh/pdf/p000043.html.
2. Albala DM, Turk TM, Fulmer BR, Koleski F, Andriole G, Davis BE, Eure GR, Kabalin JN, Lingeman J, Nuzzarello J, Sundaram C. Periurethral transurethral microwave thermotherapy for the treatment of benign prostatic hyperplasia: an interim 1-year safety and efficacy analysis using the TherMatrx TMx-2000. Tech Urol. Dec 2000;6(4):288-93.
3. Tepera C, Albala D, Andriole G, Davis BE, Kabalin JN, Lingeman, Nuzzarello J, Eure GR. Transurethral microwave thermotherapy (TUMT) using the TherMatrx TMX-2000. Improved sexual function exhibited in a randomized, blinded study comparing TUMT with a sham procedure in patients with benign prostatic hyperplasia (BPH). 52nd Annual James C. Kimbrough Urological Seminar Jan 26-21, 2005. Honolulu, Hawaii.